BR112012024618A2 - usos de inibidores de dgat1 - Google Patents

usos de inibidores de dgat1

Info

Publication number
BR112012024618A2
BR112012024618A2 BR112012024618A BR112012024618A BR112012024618A2 BR 112012024618 A2 BR112012024618 A2 BR 112012024618A2 BR 112012024618 A BR112012024618 A BR 112012024618A BR 112012024618 A BR112012024618 A BR 112012024618A BR 112012024618 A2 BR112012024618 A2 BR 112012024618A2
Authority
BR
Brazil
Prior art keywords
dgat1 inhibitor
chylomicronemia syndrome
dgat1
disease
prevention
Prior art date
Application number
BR112012024618A
Other languages
English (en)
Inventor
Meyers Charles
H Serrano-Wu Michael
Thuren Tom
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44170024&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012024618(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112012024618A2 publication Critical patent/BR112012024618A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

usos de inibidores de dgat1. a presente invenção diz respeito ao uso de um inibidor de dgat1, ou um sal farmaceuticamente aceitável ou éster do mesmo, para a prevenção, atraso da progressão ou tratamento de uma doença ou condição que é selecionada de síndrome de quilomicronemia, síndrome de quilomicronemia familial e hiperlipoproteinemia tipo v. a presente invenção ainda diz respeito ao uso de uma composição farmacêutica compreendendo um inibidor de dgat1, ou um sal farmaceuticamente aceitável ou éster do mesmo, para a prevenção, atraso da progressão ou tratamento de uma doença ou condição que é selecionada de síndrome de quilomicronemia, síndrome de quilomicronemia familial e hiperlipoproteinemia tipo v.
BR112012024618A 2010-03-30 2011-03-29 usos de inibidores de dgat1 BR112012024618A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31881410P 2010-03-30 2010-03-30
PCT/US2011/030234 WO2011123401A1 (en) 2010-03-30 2011-03-29 Uses of dgat1 inhibitors

Publications (1)

Publication Number Publication Date
BR112012024618A2 true BR112012024618A2 (pt) 2019-09-24

Family

ID=44170024

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024618A BR112012024618A2 (pt) 2010-03-30 2011-03-29 usos de inibidores de dgat1

Country Status (19)

Country Link
US (1) US9061012B2 (pt)
EP (1) EP2552441B1 (pt)
JP (2) JP2013523746A (pt)
KR (1) KR20130073884A (pt)
CN (1) CN102834099B (pt)
AU (1) AU2011235301B2 (pt)
BR (1) BR112012024618A2 (pt)
CA (1) CA2792269A1 (pt)
CL (1) CL2012002716A1 (pt)
ES (1) ES2586127T3 (pt)
MA (1) MA34097B1 (pt)
MX (1) MX2012011333A (pt)
NZ (1) NZ602125A (pt)
RU (1) RU2012145950A (pt)
SG (1) SG183529A1 (pt)
TN (1) TN2012000458A1 (pt)
TW (1) TW201136916A (pt)
WO (1) WO2011123401A1 (pt)
ZA (1) ZA201206456B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
RU2014147220A (ru) * 2012-04-25 2016-06-10 Корея Рисерч Инститьют Оф Кемикал Текнолоджи Новое бета-аланиновое производное, его фармацевтически приемлемые соли и фармацевтическая композиция, включающая его в качестве активного ингредиента
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
AU2014216137B2 (en) * 2013-02-14 2018-05-10 Ionis Pharmaceuticals, Inc. Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
LT3119384T (lt) 2014-03-20 2018-11-26 Cymabay Therapeutics, Inc. Intrahepatinių cholestazinių ligų gydymas
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3160458A1 (en) * 2014-06-26 2017-05-03 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
UA126458C2 (uk) 2018-02-13 2022-10-05 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
JP2021518431A (ja) 2018-03-16 2021-08-02 アンジ ファーマシューティカルズ インコーポレーテッド 重度の便秘を治療するための組成物及び方法
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CA3121552A1 (en) * 2018-11-30 2020-06-04 Hdl Therapeutics, Inc Methods for treating lipid-related diseases including xanthomas, carotid artery stenoses, and cerebral atherosclerosis
JP2021001143A (ja) * 2019-06-21 2021-01-07 小林製薬株式会社 乳び血漿改善剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045439A1 (en) 1996-05-30 1997-12-04 The Trustees Of Columbia University In The City Of New York Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
EP1090026B1 (en) 1998-06-24 2008-08-27 The J. David Gladstone Institutes Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
MXPA05005425A (es) 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
DE10331202A1 (de) * 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
JP2007501801A (ja) 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
US20070249620A1 (en) 2004-07-02 2007-10-25 Hitoshi Kurata Urea Derivative
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1805156B1 (en) 2004-10-15 2010-12-22 Bayer HealthCare LLC Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
JP2006166742A (ja) * 2004-12-14 2006-06-29 Japan Health Science Foundation 高トリグリセリド血症の成因となる２種類のリポタンパクリパーゼ（ｌｐｌ）遺伝子変異及びそれを利用した高トリグリセリド血症を診断するためのｌｐｌ変異検出キット
SI2402317T1 (sl) * 2006-03-31 2013-10-30 Novartis Ag DGAT inhibitor
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009119534A1 (ja) * 2008-03-26 2009-10-01 第一三共株式会社 新規テトラヒドロイソキノリン誘導体

Also Published As

Publication number Publication date
US9061012B2 (en) 2015-06-23
EP2552441A1 (en) 2013-02-06
TW201136916A (en) 2011-11-01
CA2792269A1 (en) 2011-10-06
CN102834099A (zh) 2012-12-19
AU2011235301B2 (en) 2013-07-18
NZ602125A (en) 2014-01-31
AU2011235301A1 (en) 2012-10-11
KR20130073884A (ko) 2013-07-03
JP2016216466A (ja) 2016-12-22
ES2586127T3 (es) 2016-10-11
MX2012011333A (es) 2012-11-16
CL2012002716A1 (es) 2013-01-25
TN2012000458A1 (en) 2014-01-30
RU2012145950A (ru) 2014-05-10
MA34097B1 (fr) 2013-03-05
WO2011123401A1 (en) 2011-10-06
JP6251321B2 (ja) 2017-12-20
ZA201206456B (en) 2013-05-29
SG183529A1 (en) 2012-10-30
EP2552441B1 (en) 2016-05-04
JP2013523746A (ja) 2013-06-17
CN102834099B (zh) 2015-05-27
US20130023495A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
BR112012024618A2 (pt) usos de inibidores de dgat1
PH12017501306A1 (en) Inhibitors of histone demethylases
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
BR112014009932A2 (pt) derivados de hidroxamato para inibidores da hdac e composição farmacêutica contendo os mesmos
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
BR112012019529A2 (pt) inibidores de d-nitrosoglutationa redutase
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
BR112013011441A2 (pt) composto, composição farmacêutica, e, uso de um composto
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BRPI1007092B8 (pt) Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato
PH12016502353A1 (en) Pharmaceutical composition
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
TW201613577A (en) Pharmaceutical combinations
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
BR112016026470A8 (pt) composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
BR112012026285A2 (pt) combinação de compostos orgânicos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.